Efficacy and Safety of Azithromycin in Patients With Bronchiolitis Obliterans

• Status: Completed
• Trial end date: 2011-07-21
• Target enrollment: 0
• Participant gender: All

Summary

Placebo-controlled, double-blind, randomized study. Post-infectious bronchiolitis obliterans (PIBO) patients aged 5 years and older of both sexes were enrolled.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Claudio Castanos
• Treatments: Azithromycin

Criteria

Inclusion Criteria:

• Patients with diagnosis of Bronchiolitis obliternas

• older than 5 years

• Ability to perform pulmonary function test

Exclusion Criteria:

• Not being able to perform lung function study adequately

• Other causes of chronic lung disease (bronchopulmonary dysplasia, cystic fibrosis, primary or secondary immune deficiency)

• Previous history of portal hypertension, liver cirrhosis, splenomegaly or chang in normal values of laboratory at the start of the study.

• History of hypersensitivity to macrolides